26 results about "Serum uric acid level" patented technology

The invention discloses a traditional Chinese medicine and probiotic composition and application thereof, and belongs to the technical field of medicines. The composition is prepared from a traditional Chinese medicine extract and lactobacillus brevis DMU22441 (the preservation number is CGMCC No.65301), wherein the traditional Chinese medicine extract is prepared from fructus gardeniae, rhizoma phragmitis and flos sophorae according to the mass ratio of 1: 1: 1. The traditional Chinese medicine extract is prepared through an ethanol extraction method, and the viable count of probiotics is 10 < 9 > CFU / day. According to the composition, through a three-in-one synergistic mechanism of inhibiting synthesis, promoting excretion and regulating flora, the serum uric acid level is remarkably reduced, renal function impairment is improved, and intestinal flora imbalance is regulated. The invention provides an efficient and safe multi-target solution for the treatment of hyperuricemia and complications thereof, and has significant clinical application value.

The invention discloses a preparation method of an astragalus extract with a uric acid reducing effect, and belongs to the technical field of biological medicines. The method comprises the following steps: concentrating an ethanol extract of radix astragali, extracting by using n-butyl alcohol, ethyl acetate and petroleum ether respectively, and concentrating an extract to obtain n-butyl alcohol, ethyl acetate and petroleum ether extraction parts and residual parts respectively, so as to obtain an n-butyl alcohol extract, namely the radix astragali extract for reducing uric acid. Efficacy experiments show that the normal butanol extraction part of the ethanol extract of the astragalus membranaceus can obviously reduce the serum uric acid level (SUA) of a mouse with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) and effectively improve kidney injury caused by the hyperuricemia. The uric acid reducing effect of the radix astragali n-butyl alcohol extract is close to that of a clinical drug allopurinol, and the radix astragali n-butyl alcohol extract has wide development and application prospects in the aspect of relieving hyperuricemia.

The application discloses application of white ginseng mushroom in preparation of a medicine for treating hyperuricemia, and belongs to the technical field of deep processing of edible mushrooms. The white ginseng mushroom is vacuum freeze-dried, ground into powder, other traditional Chinese medicine ingredients are extracted, concentrated, and spray-dried into powder; the white ginseng mushroom powder is mixed with sodium carboxymethyl cellulose and guar gum solution to form a mushroom suspension colloid, the microcapsules are collected after being dropped into a calcium-containing aqueous solution; the microcapsules are immersed in a high polymer compound solution for treatment, finally mixed with a stabilizer paste, and then filled after being treated by a high-pressure homogenizer and sterilized. Compared with the prior art, the medicine has good stability in simulated gastric juice, can be quickly released in simulated intestinal juice, significantly improves the bioavailability and curative effect of the medicine, can effectively reduce the serum uric acid level, improve liver and kidney functions, and regulate the intestinal flora structure, and has a significant uric acid-lowering effect and multi-target synergistic effect.

The invention discloses application of rosmarinic acid in preparation of a medicine or health food for preventing and treating hyperuricemia of a patient with renal insufficiency. The medicine for preventing and treating hyperuricemia of the patient with renal insufficiency is an XOD inhibitor or an ABCG2 gene expression promoter. The rosmarinic acid can significantly reduce the serum uric acid level of HUA mice induced by high purine diet, promote ABCG2-mediated intestinal uric acid excretion, and relieve HUA-induced intestinal inflammation and barrier injury by adjusting intestinal flora. The rosmarinic acid is safe and free of toxic and side effects, and has very important application prospects.

The invention discloses an application of parabacteroides dieldrii in preparation of a product for treating hyperuricemia. The activity of xanthine oxidase is inhibited through the parabacteroides dieldrii, uric acid related transporters are changed, and damaged organs are protected to play a uric acid reducing effect, so that chronic hyperuricemia is improved. In vitro, the parabacteroides dieldrii can inhibit the activity of xanthine oxidase. On the animal level, the parabacteroides dielsii can relieve liver and kidney injuries caused by hyperuricemia and can repair the injured intestinal barrier at the same time. Therefore, a design thought can be provided for an intestinal flora uric acid reducing preparation, so that a new intestinal flora target is provided for clinical treatment of hyperuricemia. According to the present invention, the activity of xanthine oxidase is inhibited in vitro, the uric acid transporter URAT1 in the kidney is reduced in vivo, the uric acid excretion transporter ABCG2 is increased, and the liver and kidney injury and the intestinal barrier damage caused by hyperuricemia are relieved so as to reduce the serum uric acid level and improve the hyperuricemia;

The application discloses a compound capable of treating gout, which is a compound shown in a general formula (I) or a pharmaceutically acceptable salt thereof, and the compound can reduce the serum uric acid level of a hyperuricemia rat model, and has potential application values in anti-gout drugs, anti-hyperuricemia drugs and the like.

The present application relates to the field of biotechnology, in particular to astaxanthin and dihydroquercetin co-loaded liposome and its application in preparation of uric acid-lowering products. According to the steps of "in vitro function screening - optimal ratio determination - co-loaded liposome construction - surface coating and stabilization treatment - uric acid-lowering application verification", the obtained system is verified through physicochemical characterization, stability test and animal experiment. The results show that the co-loaded liposome can reduce the serum uric acid level of high uric acid model mice, inhibit the activity of liver xanthine oxidase, and improve the related indexes of kidney function and histopathological damage.

Described herein is an improved method of treating a patient in need of such treatment with iloperidone or an active metabolite thereof wherein the patient has a gout history or carries a genetic variant associated with an increase in serum uric acid concentration induced by iloperidone. The improved method comprises monitoring a serum uric acid level of a patient; when the serum uric acid level of the patient exceeds a reference level, a uric acid lowering treatment is initiated or a dose thereof is increased.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

The invention provides an application of pithecellobium clypearia, and discloses an application of 7-galloyl telicolor flavane in resisting inflammation, inhibiting xanthine oxidase activity and treating hyperuricemia related diseases for the first time. Through enzyme inhibition tests, molecular docking and molecular dynamics simulation, the inhibition effect and the action mechanism of the 7-galloyl tericolor flavane on the activity of xanthine oxidase are discussed, the 7-galloyl tericolor flavane has excellent xanthine oxidase inhibition activity, and the half inhibitory concentration IC50 value of the 7-galloyl tericolor flavane is 6.75 + / -0.67 mu M. Experiments prove that the 7-galloyl telicolor flavane can remarkably reduce the serum uric acid level of a hyperuricemia mouse model, can reduce the oxidative stress level of a mouse, protects liver and kidney from being damaged during oxidative stress, and shows that the 7-galloyl telicolor flavane can be used for treating kidney injury caused by uric acid, and has a good application prospect. The compound has potential application value in the aspects of anti-gout drugs, anti-hyperuricemia drugs and the like.

This invention belongs to the field of traditional Chinese medicine technology, and provides a compound traditional Chinese medicine extract for lowering uric acid, its preparation, and application. Using hawthorn, astragalus, poria cocos, jujube, and tangerine peel as raw materials, this invention obtains ethanol extract S1 and water extract S2 through ethanol extraction and water extraction. Both S1 and S2 have antioxidant activity, targeting DPPH and ABTS. + The free radicals exhibit significant scavenging capabilities and can effectively inhibit xanthine oxidase activity. Furthermore, S1 and S2 can reduce serum and liver XOD activity in hyperuricemic mice, improve liver and kidney function indicators such as AST, ALT, TP, UREA, SCr, and CysC, and decrease serum uric acid levels in a dose-dependent manner; high doses can lower uric acid levels below normal. The extract of this invention possesses uric acid-lowering, antioxidant, and liver and kidney protective effects, showing good therapeutic effects on hyperuricemia and good protective and preventive effects against liver and kidney damage caused by hyperuricemia.

The invention discloses a novel application of a Guangkang capsule medicine. According to the application of the Gukang capsule medicine in preparation of the medicine for treating gout, the medicine for treating gout is a medicine preparation prepared from an extract obtained by mixing and decocting 570 g of roots of Japanese banana, 400 g of creeping oxalis, 600 g of fructus psoraleae and 300 g of radix dipsaci with water, 150 g of pseudo-ginseng fine powder, 30 g of fine powder of the roots of Japanese banana and pharmaceutically acceptable auxiliary materials. Animal experiments show that the serum uric acid level of a hyperuricemia model mouse can be remarkably reduced, and joint swelling and inflammatory cell infiltration are relieved. Clinical observation further proves that the traditional Chinese medicine composition has a good curative effect on improvement of arthralgia, limited activity and other symptoms of gout patients, is relatively high in safety and does not have obvious adverse reaction.

The present disclosure discloses Lactobacillus reuteri CCFM1132 capable of relieving hyperuricemia and application thereof, which belongs to the technical field of microorganisms. The L. reuteri CCFM1132 can reduce serum uric acid levels of mice with hyperuricemia, inhibit the activity of serum and liver xanthine oxidase (XOD), and reduce the occurrence of hyperuricemia and gout; reduce serum creatinine levels, reduce serum total triglyceride (TG) levels, and inhibit the activity of serum alkaline phosphatase (ALP); and promote the expression of ileum uric acid transporter ABCG2. The L. reuteri CCFM1132 of the present disclosure can be used for preparing functional bacterial agents, food and medicines for relieving hyperuricemia and gout, and has a wide application prospect.

The present application belongs to the technical field of biological medicine, and provides a cordyceps militaris mycelium extract with uric acid reducing activity, a preparation method and application thereof. 60 The preparation method comprises the following steps: fermenting and culturing a cordyceps militaris strain, collecting the mycelium after fermentation is completed; freezing and drying the mycelium, and then performing Coγ-ray irradiation pretreatment to obtain pretreated mycelium; performing ultrasonic-assisted extraction on the pretreated mycelium to obtain the cordyceps militaris mycelium extract. It is verified through experiments that the cordyceps militaris mycelium extract prepared by the present application belongs to the non-toxic level and has high edible safety. The extract can significantly inhibit xanthine oxidase activity from three levels of in vitro, cells and animals in vivo, can obviously reduce the serum uric acid level of mice and promote the excretion of uric acid in vivo; at the same time, the extract has good regulation and repair effects on relieving liver and kidney damage caused by high uric acid and improving liver lipid metabolism disorder, and has good development value and market application prospect.

The invention relates to probiotics with an effect of reducing uric acid and application of the probiotics in the field of microorganisms. The probiotic is lactobacillus rhamnosus, is named as CHP003, is preserved in the China General Microbiological Culture Collection Center on December 8, 2022, and has the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.26176. The invention further discloses a preparation method of the probiotic. The lactobacillus rhamnosus CHP003 strain has a plurality of probiotic effects, including reduction of the activity of xanthine oxidase (XOD) and effective reduction of the serum uric acid level of a hyperuricemia model, and provides a new thought and means for treatment and prevention of metabolic diseases such as hyperuricemia, gout and the like.

The invention discloses an application of cinchona element Ia as a uric acid lowering drug, and finds that the cinchona element Ia has a remarkable inhibition effect on expression of GLUT9 protein for the first time, and reabsorption of the kidney to uric acid can be effectively reduced by inhibiting expression of the GLUT9 protein, so that excretion of the uric acid from urine is promoted, the serum uric acid level is reduced, and the toxic and side effects of the kidney are reduced. And a new effective way is provided for treatment of hyperuricemia and gout.

The invention relates to application of obakunone in preparation of uric acid lowering drugs. The obakunone can be used for lowering serum uric acid level and liver tissue uric acid content. According to the experiment, a high-fat feed induced metabolism-related fatty liver disease mouse model is adopted, obakunone is administrated through intragastric administration, and the influence of obakunone on the uric acid level is observed; the result shows that the serum uric acid level and the liver tissue uric acid level of the obakunone intervention group are reduced. Meanwhile, obakunone can reduce the content of triglyceride in liver tissue and improve liver lipid deposition.

The invention belongs to the technical field of natural medicines, and particularly relates to application of carnosol in preparation of medicines for treating hyperuricemia or improving kidney injury caused by hyperuricemia. It is found for the first time that the carnosol can significantly reduce the serum uric acid level of a mouse with hyperuricemia, promote excretion of kidney uric acid and also significantly improve renal function impairment and renal structure impairment caused by hyperuricemia. Therefore, the carnosol can be used for preparing the medicine for treating the hyperuricemia and the medicine for treating the kidney injury caused by the hyperuricemia.

The invention relates to the technical field of traditional Chinese medicine compound preparations, and discloses a pharmaceutical composition and application thereof in preparation of drugs for preventing and treating hyperuricemia and gout, the pharmaceutical composition takes gentiana macrophylla as a monarch material, and focuses on expelling wind-damp, clearing damp-heat, relieving arthralgia, inhibiting uric acid generation, and promoting kidney excretion to reduce blood uric acid. Gastrodia elata and radix cyathulae serve as ministerial drugs, and gastrodia elata dispels wind, dredges collaterals The radix cyathulae has the effects of easing joint movement, guiding the medicine to move downwards and inducing And the raw lalang grass rhizome is used for reducing fever and causing diuresis, and guiding turbidity to go out. Ligusticum wallichii is used as a guide to activate blood and qi, dispel wind and relieve pain. Through targeted adjustment of the ratio of the raw materials and scientific compatibility, the effects of reducing the level of serum uric acid, remarkably improving the activity of liver uricase, synchronously improving renal function indexes, relieving hepatic and nephropathy damage, resisting acute gout and the like are achieved, and the medicine effect is remarkable.

This invention discloses a xanthine transporter mutant and its applications, belonging to the field of biotechnology. Using live bacterial cells obtained from recombinant Escherichia coli Nissle 1917 containing xanthine transporter protein cultured in M9 medium as the transporter, and xanthine as the substrate, this invention reduces the extracellular xanthine concentration. Animal experiments showed that gavage administration of the xanthine transporter mutant effectively reduced the xanthine content in the intestine and serum uric acid levels in hyperuricemic mouse models. The invention also discloses that the transport activity of the xanthine transporter mutant changes; in a reaction system containing M9 medium with a final xanthine concentration of 5-20 μg / mL, the transport efficiency of xanthine substrate reaches 83%-100%, and the maximum conversion rate of the substrate is increased by 110-120% compared to the wild type. This invention provides a new treatment method and direction for the treatment of hyperuricemia and various chronic diseases caused by high uric acid.

The present disclosure relates to the field of medicaments, and particularly to use of Liriodendron chinense (Hemsl.) Sarg, or an extract thereof in the preparation of a medicament for reducing a serum uric acid level and preventing and treating uric acid nephropathy, and belongs to the field of medicaments. In one aspect, the present disclosure provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level. In another aspect, the present disclosure further provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for treating and / or preventing uric acid nephropathy.

This invention provides a method for constructing a rat model of hyperuricemia, belonging to the field of animal model construction technology. SPF-grade male rats were selected and, after adaptive feeding, were administered inosine (5-15 mg / kg), potassium oxonate (150-160 mg / kg), and hypoxanthine (100-200 mg / kg). Inosine and potassium oxonate were administered intraperitoneally, while hypoxanthine was administered subcutaneously. Experimental results showed that serum uric acid levels significantly increased one hour after modeling, and the hyperuricemic state could be maintained for up to 24 hours, significantly better than traditional models. Simultaneously, serum urea nitrogen and creatinine levels did not show significant increases, indicating that the model did not cause serious kidney damage. The hyperuricemia model constructed by this invention has a rapid onset of action, a long duration of hyperuricemia, and minimal kidney damage, making it suitable for the screening and evaluation of anti-hyperuricemia drugs.

The invention discloses application of an AKK PROBIO strain in preparation of uric acid lowering drugs, and belongs to the technical field of microorganisms. Effective methods for treating hyperuricemia with small side effects in the prior art are still limited. In order to solve the problem, the invention provides an AKK PROBIO strain, and the preservation number of the AKK PROBIO strain is CGMCC (China General Microbiological Culture Collection Center) No.20955. The bacterium can obviously reduce the serum uric acid level of a hyperuricemia mouse, the curative effect of the bacterium is derived from a multi-system synergistic effect mechanism, the intestinal-renal axis steady state can be recovered, and hyperuricemia is improved through the following four key ways: (1) inhibiting uric acid biosynthesis; (2) the excretion of kidney uric acid is enhanced; (3) inflammation and oxidative stress reaction can be relieved; and (4) reconstructing intestinal flora balance.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

This invention discloses the application of aspirin eugenol ester in the preparation of drugs for improving hyperuricemia. While maintaining the pharmacological activities of aspirin and eugenol, aspirin eugenol ester shields the carboxyl group of aspirin, reducing the gastrointestinal irritation and other side effects of aspirin upon ingestion. Simultaneously, it overcomes the irritating odor and instability of eugenol, enabling it to exert therapeutic effects in improving hyperuricemia. Through multiple pathways, including inhibiting uric acid production, promoting uric acid excretion, activating antioxidant pathways, and inhibiting inflammatory and apoptotic signals, it significantly reduces serum uric acid levels in hyperuricemic rats, thereby improving hyperuricemia.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.